Literature DB >> 14998975

Blocking of the placental immune-modulatory ferritin activates Th1 type cytokines and affects placenta development, fetal growth and the pregnancy outcome.

R Nahum1, O Brenner, M A Zahalka, L Traub, F Quintana, C Moroz.   

Abstract

BACKGROUND: Placenta immunomodulatory ferritin (PLIF) cDNA was recently cloned from the human placenta, where it is expressed in syncytiotrophoblast and decidual mononuclear cells. PLIF and its subcloned bioactive domain (C48), expressed in Escherichia coli, are immunosuppressive proteins and induce pronounced IL-10 production in vitro and in vivo. METHODS AND
RESULTS: PLIF serum level, measured by enzyme-linked immunosorbent assay, was elevated in pregnant mice throughout gestation and declined towards delivery. Blocking of PLIF activity by vaccination of mice with C48 prior to mating inhibited pregnancy development. Passive transfer of anti-C48 immunoglobulin (Ig) starting at 3.5-12.5 days post coitum (dpc) resulted in high rate of embryo resorption. Furthermore, treatment with anti-C48 Ig resulted in placental and embryonal growth restriction. At gestation day 13.5, growth retardation was especially notable in the placentae, while at 16.5 dpc it was pronounced in the embryos. Histopathological examination revealed that experimental placentae were globally hypoplastic and the labyrinth was strikingly pale and contained less maternal blood compared with control. Immune-activated spleen cells harvested at 13.5 dpc from anti-C48 Ig-treated pregnant mice secreted in vitro increased level of Th1 cytokines (IL-2, TNF-alpha, IL-12) and decreased level of Th2 cytokines (IL-10, IL-4, IL-5, IL-6) as compared with the level of the respective cytokines secreted by spleen cells from control pregnant mice.
CONCLUSION: This study provides the first in vivo evidence that PLIF plays a major role in placentation and embryonic growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14998975     DOI: 10.1093/humrep/deh099

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Preventive and therapeutic potential of placental extract in contact hypersensitivity.

Authors:  Youn Son Kim; Jang-June Park; Yukimi Sakoda; Yuming Zhao; Katsuya Hisamichi; Tai-Ichi Kaku; Koji Tamada
Journal:  Int Immunopharmacol       Date:  2010-07-07       Impact factor: 4.932

2.  Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model.

Authors:  Marisa Halpern; Muayad A Zahalka; Leonid Traub; Chaya Moroz
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

3.  Decidual NR2F2-Expressing CD4+ T Cells Promote TH2 Transcriptional Program During Early Pregnancy.

Authors:  Yikong Lin; Di Zhang; Yangyang Li; Yunyun Li; Bin Li; Meirong Du
Journal:  Front Immunol       Date:  2021-05-18       Impact factor: 7.561

4.  Synthetic PreImplantation Factor (PIF) prevents fetal loss by modulating LPS induced inflammatory response.

Authors:  Nicoletta Di Simone; Fiorella Di Nicuolo; Riccardo Marana; Roberta Castellani; Francesco Ria; Manuela Veglia; Giovanni Scambia; Daniel Surbek; Eytan Barnea; Martin Mueller
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

Review 5.  Pregnancy-Related Immune Changes and Demyelinating Diseases of the Central Nervous System.

Authors:  Ke Qiu; Qiang He; Xiqian Chen; Hui Liu; Shuwen Deng; Wei Lu
Journal:  Front Neurol       Date:  2019-10-09       Impact factor: 4.003

6.  A safe vaccine (DV-STM-07) against Salmonella infection prevents abortion and confers protective immunity to the pregnant and new born mice.

Authors:  Vidya Devi Negi; Arvindhan G Nagarajan; Dipshikha Chakravortty
Journal:  PLoS One       Date:  2010-02-10       Impact factor: 3.240

7.  The novel C24D synthetic polypeptide inhibits binding of placenta immunosuppressive ferritin to human T cells and elicits anti-breast cancer immunity in vitro and in vivo.

Authors:  Inna Solodeev; Muayad A Zahalka; Chaya Moroz
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.